Last reviewed · How we verify
NCT06054932
Safety, Tolerability, and Immunogenicity of LK101 Alone in Participants With Incurable Solid Tumors
Phase 1 trial testing LK101 injection in Advanced Solid Tumor in 18 participants. Status unknown.
30 December 2025
Quick facts
| Lead sponsor | Beijing Likang Life Science and Tech Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 18 |
| Start date | 5 September 2023 |
| Primary completion | 30 December 2025 |
| Estimated completion | 30 March 2026 |
| Sites | 2 locations across China |
Drugs / interventions tested
- LK101 injection — full drug profile →
- LK101 injection — full drug profile →
Conditions studied
- Advanced Solid Tumor — all drugs for Advanced Solid Tumor →
Sponsor
Beijing Likang Life Science and Tech Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Advanced Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is an open-labeled, single-center phase I study in patients with incurable advanced solid tumors, who failed with all previous standard therapy. The aim is to observe and evaluate the safety, tolerability, and immunogenicity of LK101 injection.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Current progress in neoantigen-based dendritic cell vaccines for solid tumors.
Li Y, Abudureheman A, Xu J. · · 2025 · cited 2× · PMID 41024613 · DOI 10.20892/j.issn.2095-3941.2025.0267 -
Neoantigen-driven personalized tumor therapy: An update from discovery to clinical application.
Xie N, Shen G, Huang C, Zhu H. · · 2025 · cited 2× · PMID 40757404 · DOI 10.1097/cm9.0000000000003708
Verify or expand the search:
- PubMed search for NCT06054932
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Solid Tumor
Currently open trials in the same condition.
- NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
- NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
- NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
- NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06054932 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Likang Life Science and Tech Co., Ltd.
- Last refreshed: 26 September 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06054932.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing